News · Clinical trials

REIMAGINE 2: CagriSema Beats Semaglutide on HbA1c by 1.91 Points With 14.2% Weight Loss

The furthest-advanced next-generation combination reports in type 2 diabetes, ahead of an FDA response expected during 2026.

Event date 2026-06-30 · Published 2026-07-24 · EV-0813

What was reported

REIMAGINE 2 enrolled 2,728 adults with type 2 diabetes and excess body weight, and reported CagriSema reducing HbA1c by 1.91 percentage points more than semaglutide alone, alongside 14.2% weight loss.

CagriSema combines cagrilintide, a long-acting amylin analogue, with semaglutide. Amylin is a separate hormonal pathway from GLP-1, and the combination hypothesis mirrors the one that produced tirzepatide's dual GIP/GLP-1 mechanism: acting on two pathways delivers more than either alone.

Reading the two figures together

The HbA1c result is the headline in a diabetes trial and it is substantial — nearly two percentage points beyond an already effective comparator.

The 14.2% weight figure needs context. This is a type 2 diabetes population, where weight outcomes for GLP-1 drugs are typically smaller than in populations without diabetes. Comparing 14.2% here against about 20.9% for tirzepatide in SURMOUNT-1 — a trial that excluded people with diabetes — is not a like-for-like comparison, and it will be made anyway.

The relevant CagriSema weight comparison is the REDEFINE programme in obesity, and head-to-head work against tirzepatide.

Status

CagriSema is not approved. An FDA response is expected during 2026. It cannot be lawfully supplied by any provider or compounded by any pharmacy — compounding a copy of an available approved product is generally prohibited, and this is not an approved product at all.

That distinction is worth stating plainly because unapproved compounds in this class attract a grey market. Anything sold today as CagriSema is outside the regulated supply chain entirely, with no prescriber, no pharmacy licence and no recourse.

What approval would change

For patients with type 2 diabetes and obesity, a genuinely different option with a distinct mechanism. For the market, a third major manufacturer position in a category currently split between two.

What it would not change immediately is price. New approvals launch at brand pricing, and coverage takes time. The Wegovy pill and Foundayo are the useful precedents: both launched with self-pay from $149 and savings programmes bringing eligible commercially insured patients to around $25, but neither arrived cheap on day one for everyone.

The pattern worth noticing

Every advance in this field for three years has come from adding mechanisms or raising doses: GIP to GLP-1 in tirzepatide, glucagon on top of both in retatrutide, amylin alongside GLP-1 in CagriSema, and simply more semaglutide in STEP UP.

That is a productive research direction and it has a consequence for patients: the approved landscape is likely to keep changing. A twelve-month prepayment made today forecloses a market still in motion, which is an argument for keeping the exit open even where month-to-month pricing costs more.

Questions readers actually ask